Physician profile
Kenneth W Jackson
NPI 1487606943
$1,717.26
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $710 · 2020: $93.65 · 2021: $29.54 · 2022: $406 · 2023: $479.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $479.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $478.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $764.56 | 2019-2023 | |
| Pfizer INC. | $195.19 | 2019-2023 | |
| Astellas Pharma US INC | $192.08 | 2019-2023 | Veozah, Myrbetriq |
| Coopersurgical, INC. | $78.15 | 2019-2023 | Endosee |
| Daiichi Sankyo INC. | $62.77 | 2020-2023 | Injectafer |
| Ethicon US, LLC | $61.51 | 2023 | Enseal X1, Enseal |
| Mayne Pharma Commercial LLC | $52.59 | 2023 | |
| Therapeuticsmd, INC. | $42.87 | 2019-2020 | |
| Organon LLC | $41.53 | 2022-2023 | Nexplanon |
| Smith+Nephew, INC. | $33.36 | 2019 | |
| Coloplast Corp | $31.02 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $27.45 | 2022 | |
| Axonics, INC. | $25.62 | 2022 | |
| Myovant Sciences INC. | $25.43 | 2022 | |
| Sumitomo Pharma America, INC. | $22.99 | 2023 | Myfembree |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Osiris Therapeutics INC. | $20.71 | 2019 | |
| Boston Scientific Corporation | $15.18 | 2023 | Solyx Sis System |
| Urovant Sciences INC | $12.71 | 2022 | |
| Mission Pharmacal Company | $11.54 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Jackson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.